Reducing end-of-life costs will do little to curb the growth in Medicare spending overall. But end-of-life care provision should be reformed to match the values of patients.

Incorporating the effects of health into an analysis of economic disparities in America dramatically affects our understanding of wealth levels across groups--particularly across races.

New medical technologies are often argued to be a leading force behind the growth in health care spending.

Anupam B. Jena and Tomas J. Philipson argue that further use of cost-effectiveness analysis to curb health care spending may do more harm than good.

In a new AEI Press book, Anupam B. Jena and Tomas J. Philipson argue that health care cost-effectiveness criteria may constrain future innovation.

Almost all pharmaceuticals are purchased by third parties (insurance or government) through the use of reimbursements. Yet, as University of Chicago health economists Anupam B. Jena and Tomas J. Philipson demonstrate in their new book, Innovation and Technology Adoption in Health Care Markets (AEI Press, August 2008), reimbursement levels based...

The use of cost-effectiveness criteria, while lowering the cost of health care in the short term, threatens to harm future patients by stifling vital medical innovations.

The Republicansruined a great opportunity to clear the House floor for an extended and gratifying debate on Iraq and even on the broader war on terror--a debatethe nation needs.